TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17302367
Drug: LB80380 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: LB80380 120 mg once per day
Study: 17302367
Drug: LB80380 240
Approvals — FDA: no, EMA: no, PMDA: no
Description: LB80380 240 mg once per day
Study: 8811473
Drug: 1% aqueous
Normalized name: Zotane-HC 0.1%-1%-1% Aqueous Otic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% aqueous solution of delmopinol hydrochloride applied 2 times a day for 7 days
Study: 8811473
Drug: 1% aqueous
Normalized name: Zotane-HC 0.1%-1%-1% Aqueous Otic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% aqueous solution of delmopinol hydrochloride applied on previously placebo-treated surfaces
Study: 27235114
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy intervention group (MTG)
Study: 24877181
Drug: Azacitidine 25-100
Normalized name: azacitidine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azacitidine 25-100 mg/m2 SC doses in patients with normal renal function (n=21)
Study: 24877181
Drug: Azacitidine 75
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azacitidine 75 mg/m2 SC doses for 5 consecutive days in patients with severe renal impairment (n=6)
Study: 24877181
Drug: Azacitidine 75
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azacitidine 75 mg/m2 SC doses (multiple doses)
Study: 24257722
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g whey protein
Study: 24257722
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g whey protein
Study: 22338070
Drug: 35 g
Normalized name: SODIUM CHLORIDE 0.135 g in 15 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35 g whey protein
Study: 19958428
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of three full‐face IPL treatments and six full‐face topical antioxidant applications (Group C)
Study: 19958428
Drug: Three full‐face
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three full‐face IPL treatments (Group A)
Study: 19958428
Drug: Six weekly
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Six weekly full‐face treatments of a pneumatically applied topical polyphenolic antioxidant solution (Group B)
Study: 15884262
Drug: GnRH analogue
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH analogue (50 mg oral doses)
Study: 8610901
Drug: Transnasal butorphanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transnasal butorphanol 1 mg
Study: 8610901
Drug: Transnasal butorphanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transnasal butorphanol 2 mg
Study: 8055737
Drug: Transnasal butorphanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transnasal butorphanol 4 mg
Study: 8055737
Drug: Intramuscular butorphanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular butorphanol 1 mg
Study: 8055737
Drug: Intramuscular butorphanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular butorphanol 2 mg
Study: 8055737
Drug: Intramuscular butorphanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular butorphanol 4 mg
Study: 3056221
Drug: Postoperative immunochemotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative immunochemotherapy (streptococcus pyogenes preparation (picibanil) intramuscularly every week, plus either MFC or FME chemotherapy regimen)
Study: 3056221
Drug: Surgery alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery alone (no further anticancer therapy)
Study: 17244767
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral 600-mg dose of cyclosporine with a single 100-mg oral sitagliptin dose
Study: 17244767
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral 100-mg sitagliptin dose alone
Study: 15258553
Drug: metformin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: metformin + pioglitazone 30 mg
Study: 11832307
Drug: α-blockers
Normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: α-blockers
Study: 2701034
Drug: Magnetic device
Normalized name: MAGNESIA
DrugBank: Magnesium oxide (DB01377)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnetic device therapy
Study: 786669
Drug: 1.2 mg
Normalized name: RNA 1.2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 mg methyl proscillaridin (oral administration)
Study: 786669
Drug: 1.2 mg
Normalized name: RNA 1.2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 mg methyl proscillaridin (intravenous administration)
Study: 786669
Drug: 1.2 mg
Normalized name: RNA 1.2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 mg methyl proscillaridin (oral and iv administration)
Study: 29722166
Drug: SRP plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRP plus 1% ALN gel
Study: 29722166
Drug: SRP plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRP plus AV gel
Study: 21998479
Drug: Valacyclovir 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valacyclovir 1.5 g twice daily for 12 weeks
Study: 21998479
Drug: Acyclovir 400
Normalized name: acyclovir 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir 400 mg twice daily for 12 weeks
Study: 16927137
Drug: IV pantoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV pantoprazole (40 mg once daily for 7 days)
Study: 16927137
Drug: Oral pantoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral pantoprazole (40 mg once daily for 7 days)
Study: 16927137
Drug: IV/oral pantoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV/oral pantoprazole
Study: 15742550
Drug: Enfuvirtide (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enfuvirtide (90 mg subcutaneously twice daily) plus optimized background regimen
Study: 9849404
Drug: Interferon alfa-2b
Normalized name: Interferon Alfa-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon alfa-2b (IFN-alpha 2b) as adjuvant therapy
Study: 10319136
Drug: Formulation A
Normalized name: meningococcal vaccine of unknown formulation and unknown serogroups
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation A (0.5 mg oral digoxin)
Study: 10319136
Drug: Formulation B
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation B (0.5 mg oral digoxin)
Study: 10319136
Drug: Formulation C
Normalized name: Army Liposome Formulation component monophosphoryl lipid A
DrugBank: Monophosphoryl lipid A (DB19290)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation C (0.5 mg oral digoxin, standard)
Study: 2687956
Drug: Thoracic radiation
Normalized name: Thoracol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thoracic radiation with chemotherapy
Study: 2687956
Drug: Combined modality
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined modality treatment after resection of rectal cancer
Study: 2687956
Drug: Radiation and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation and concurrent 5-fluorouracil for squamous cancers of the anal canal
Study: 53659
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of 1‐25 megaunits of penicillin
Study: 53659
Drug: Local wound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local wound irrigation with 100mg of tetracycline in solution
Study: 30714820
Drug: Single extended
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single extended release (ER) methylphenidate dose
Study: 29087804
Drug: Extraction treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extraction treatment
Study: 29087804
Drug: Air-rotor stripping
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Air-rotor stripping (ARS) treatment
Study: 29087804
Drug: Non-extraction treatment
Normalized name: Hyacinthoides non-scripta extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-extraction treatment
Study: 25373438
Drug: Prophylactic dose
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic dose low-molecular-weight heparin (LMWH) for 21 days
Study: 25373438
Drug: Saline placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline placebo injections for 21 days
Study: 23874588
Drug: Soy isoflavone
Normalized name: soy isoflavone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy isoflavone capsules (80 mg/d total isoflavones, 51 mg/d aglucon units)
Study: 21334240
Drug: Lidocaine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (50 mg Xilonibsa 10% before examination)
Study: 17109339
Drug: Cyclosporin A
Normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin A treatment for 2 weeks
Study: 17109339
Drug: Standardized antiretroviral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized antiretroviral therapy (ART)
Study: 11239186
Drug: NXY-059 (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: NXY-059 (250 mg over 1 hour followed by 85 mg/h for 71 hours)
Study: 11239186
Drug: NXY-059 (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: NXY-059 (500 mg over 1 hour followed by 170 mg/h for 71 hours)
Study: 9227720
Drug: Inhaled formoterol
Normalized name: formoterol Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled formoterol 24 micrograms twice daily
Study: 27632893
Drug: Preladenant 2
Normalized name: Preladenant
DrugBank: Preladenant (DB11864)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preladenant 2 mg BID
Study: 27632893
Drug: Preladenant 5
Normalized name: Preladenant
DrugBank: Preladenant (DB11864)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preladenant 5 mg BID
Study: 27632893
Drug: Preladenant 10
Normalized name: Preladenant
DrugBank: Preladenant (DB11864)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preladenant 10 mg BID
Study: 18849079
Drug: Sertraline (or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (or amitriptyline as a second choice) plus Interpersonal Psychotherapy modified for inpatients (IPT)
Study: 18849079
Drug: Sertraline (or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (or amitriptyline as a second choice) plus Clinical Management (CM)
Study: 12487221
Drug: DPI (Dry
Approvals — FDA: no, EMA: no, PMDA: no
Description: DPI (Dry Powder Inhaler) - 200 microg of inhaled budesonide twice daily for 1 month
Study: 12487221
Drug: pMDI +
Approvals — FDA: no, EMA: no, PMDA: no
Description: pMDI + spacer (Pressurized Metered-Dose Inhaler with spacer) - 200 microg of inhaled budesonide twice daily for 1 month
Study: 2560799
Drug: Hormones plus
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormones plus plasmapheresis
Study: 2560799
Drug: Hormones alone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormones alone
Study: 30666071
Drug: Intralesional MMR
Normalized name: varicella-zoster virus vaccine live (Oka-Merck) strain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional MMR vaccine
Study: 31650487
Drug: Phyllanthus amarus
Normalized name: Phyllanthus amarus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phyllanthus amarus (PP) by nanoparticle gel phonophoresis
Study: 25933498
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g of L-glutamine (GLN) daily for 14 days
Study: 25933498
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g of L-alanine (ALA) daily for 14 days
Study: 22378476
Drug: Modified Forced-Use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified Forced-Use Therapy (mFUT)
Study: 19763135
Drug: EPA treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPA treatment (1.8 g administered daily for 3 months)
Study: 16087985
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (10 mg Zn as sulfate daily)
Study: 16087985
Drug: Stimulation alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulation alone (weekly home visits for play demonstration and maternal-child interaction encouragement)
Study: 8673545
Drug: L-697,661 as
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-697,661 as monotherapy
Study: 8673545
Drug: L-697,661 administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-697,661 administered concomitantly with zidovudine (ZDV)
Study: 6749427
Drug: Cholestyramine (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholestyramine (24 g daily) and diet
Study: 29407226
Drug: Physical Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical Therapy Exercise
Study: 25589511
Drug: Chondroitin sulfate
Normalized name: Chondroitin Sulfate
DrugBank: Chondroitin sulfate (DB09301)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chondroitin sulfate plus glucosamine hydrochloride (CS+GH) 400 mg CS plus 500 mg GH three times a day for 6 months
Study: 30648524
Drug: Celecoxib 200
Normalized name: celecoxib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 200 mg daily for 6 months
Study: 22535977
Drug: Insulin withdrawal
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin withdrawal after 16 hours of hyperglycemia
Study: 22535977
Drug: Insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin infusion after 16 hours of euglycemia
Study: 20309389
Drug: Percutaneous adhesiolysis
Normalized name: PERCUTANEOUS INTRODUCER SET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous adhesiolysis with target delivery of lidocaine, 10% hypertonic sodium chloride solution, and non-participate betamethasone.
Study: 20309389
Drug: Caudal epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal epidural steroid injections with catheterization up to S3 with local anesthetic, steroids, and 0.9% sodium chloride solution.
Study: 15961678
Drug: PUFA-supplemented liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: PUFA-supplemented liquid oral diet (3.7 g of PUFA, 1000 mL/d for 5 days preoperatively)
Study: 12616980
Drug: Monophasic oral
Normalized name: hyoscyamine / methenamine / methylene blue / phenyl salicylate / sodium phosphate, monobasic Oral Tablet [Urelle]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monophasic oral contraceptive containing 75 micrograms of gestodene and 20 micrograms of ethinyl estradiol
Study: 12616980
Drug: Both oral
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both oral contraceptives
Study: 7500751
Drug: Desogestrel-containing oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desogestrel-containing oral contraceptive
Study: 12616980
Drug: Gestodene-containing oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gestodene-containing oral contraceptive
Study: 10361867
Drug: 15 mg/d
Normalized name: Valtoco, 15 mg/dose nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/d of folic acid and 200 mg/d of pyridoxine for 4 wk
Study: 7627722
Drug: Protein-bound polysaccharide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein-bound polysaccharide P (PSK) therapy
Study: 7627722
Drug: PSK therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSK therapy in patients with abnormal levels of alpha 1-antichymotrypsin and sialic acid
Study: 2021332
Drug: Sulfate free‐electrolyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfate free‐electrolyte lavage solution
Study: 3095080
Drug: Polyethylene glycol
Normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyethylene glycol electrolyte lavage solution
Study: 25283485
Drug: MS+G (metformin-sitagliptin
Approvals — FDA: no, EMA: no, PMDA: no
Description: MS+G (metformin-sitagliptin + glargine)
Study: 25283485
Drug: MG+S (metformin-glargine
Approvals — FDA: no, EMA: no, PMDA: no
Description: MG+S (metformin-glargine + sitagliptin)
Study: 25283485
Drug: MS+G and
Normalized name: MS-1819
DrugBank: MS-1819 (DB15004)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MS+G and MG+S
Study: 23695420
Drug: Raloxifene (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene (daily for 2 years)
Study: 19013526
Drug: 25OHD (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25OHD (25 microg/day) administration for 2 weeks
Study: 8179541
Drug: Magnesium sulphate
Normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium sulphate (4-g bolus intravenously)
Study: 2820359
Drug: Maintenance therapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance therapy (alternate-month outpatient)
Study: 2820359
Drug: Inpatient induction
Normalized name: Impatiens irvingii whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inpatient induction therapy
Study: 2820359
Drug: Outpatient induction
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient induction therapy
Study: 3323596
Drug: Cyclophosphamide treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide treatment
Study: 22224243
Drug: Neuromidin as
Normalized name: Neurokinin p
DrugBank: Substance P (DB19198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuromidin as an add-on to basic treatment
Study: 22224243
Drug: Basic treatment
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic treatment (antiaggregant, antihypertensive, cardiac and antidiabetic drugs)
Study: 15053297
Drug: Zinc containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc containing infusion
Study: 15053297
Drug: No zinc
Normalized name: ZINC OXIDE 140 mg in 1 mL TOPICAL CREAM [Lucin Organics Tinted Sunscreen SPF 30 Non Nano Zinc Oxide]
Approvals — FDA: no, EMA: no, PMDA: no
Description: No zinc containing infusion (Control)
Study: 10835438
Drug: Nalmefene (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalmefene (60 mg administered as a 10 mg bolus over 15 minutes and then a 50 mg infusion over 23.75 hours)
Study: 7901056
Drug: Intravaginal 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravaginal 2.0 mg prostaglandin E2 gel
Study: 7901056
Drug: Intravaginal 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravaginal 3.0 mg prostaglandin E2 gel
Study: 3536232
Drug: Calcitriol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitriol (1 microgram daily)
Study: 28299514
Drug: CXCR4 peptide
Normalized name: Peptide T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CXCR4 peptide antagonist LY2510924 plus carboplatin-etoposide (CE)
Study: 21282537
Drug: Vandetanib 100
Normalized name: vandetanib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vandetanib 100 mg/d plus pemetrexed 500 mg/m² every 21 days
Study: 16859122
Drug: Chemoembolization of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoembolization of bilateral internal iliac arteries with anticancer agents and gelatin sponge particles during Miles operation
Study: 11233804
Drug: Meropenem 1
Normalized name: meropenem 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meropenem 1 g i.v. every 8 hours
Study: 11233804
Drug: Ceftazidime 2
Normalized name: ceftazidime 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime 2 g i.v. every 8 hours plus Amikacin 15 mg/kg daily
Study: 8039271
Drug: Flumazenil (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil (0.5 mg, i.v. bolus)
Study: 25081818
Drug: Problem Solving
Normalized name: Solv X
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Problem Solving Therapy (PST)
Study: 25615523
Drug: Evidence-based anxiety
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evidence-based anxiety intervention (including cognitive behavioral therapy and medications)
Study: 16506042
Drug: Multidisciplinary treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidisciplinary treatment (psychological and physical sessions)
Study: 12486426
Drug: Lisinopril treatment
Normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lisinopril treatment for 6 weeks
Study: 16091636
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no lisinopril)
Study: 1416011
Drug: 0.12 mg
Normalized name: iodine 0.12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.12 mg Cl (group B)
Study: 1416011
Drug: 0.24 mg
Normalized name: vitamin A 0.24 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.24 mg Cl (group C)
Study: 2860687
Drug: Nonabine (5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonabine (5, 10, and 15 mg)
Study: 2860687
Drug: Ketazolam (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketazolam (30 and 45 mg)
Study: 20354459
Drug: Allovectin-7 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allovectin-7 (2 mg, high dose)
Study: 14668075
Drug: bupropion SR
Normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: bupropion SR (150 or 300 mg) and behavioral counseling (tailored mailings or proactive telephone counseling)
Study: 14668075
Drug: bupropion SR
Normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: bupropion SR (lower dose)
Study: 10780310
Drug: Bemiparin (3,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bemiparin (3,500 anti-Xa IU daily)
Study: 10780310
Drug: UFH (5,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFH (5,000 IU twice daily)
Study: 1521812
Drug: Dexamethasone 0.1%
Normalized name: DEXAMETHASONE 0.1% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 0.1% eye drops, 5 times daily for 5 days
Study: 1521812
Drug: Prednisolone acetate
Normalized name: Prednisolone Acetate
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone acetate 1.0% eye drops, 5 times daily for 5 days
Study: 29889310
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with epilepsy (before treatment)
Study: 29889310
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with epilepsy (after treatment)
Study: 21030704
Drug: Conventional temperature
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional temperature management (stepwise fever management with antiinflammatory drugs and surface cooling)